研究開発領域

研究出版物

2023年	Xu X, Guo Y, Luo X, Shen Z, Sun Z, Shen B, Zhou C, Wang J, Lu J, Zhang Q, Ye Y. Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI. Liver International. 2023.
2023年	Cai X, Liu X, Xie W, Ma A, Tan Y, Shang J, Zhang J, Chen C, Yu Y, Qu Y, Zhang L. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a phase 2 randomized controlled trial. Clinical Gastroenterology and Hepatology. 2023 Jul 1;21(7):1893-901.
2023年	Zhang R, Li P, Guo P, Zhou J, Wan J, Yang C, Zhou J, Liu Y, Shi S. A Pharmacokinetic Drug–Drug Interactions Study between Entecavir and Hydronidone, a Potential Novel Antifibrotic Small Molecule, in Healthy Male Volunteers. Advances in Therapy. 2023 Feb;40(2):658-70.
2022年	Zhang R, Li P, Zhou J, Guo P, Liu Y, Shi S. A novel, simple and reliable method for the determination of hydronidone and its metabolites M3 and M4 in human plasma and urine by HPLC-MS/MS and its application to a pharmacokinetic study in health Chinese subjects. Analytical Biochemistry. 2022 Oct 15;655:114842.
2017年	Liu Y, Wu J, Li Z, Luo Y, Zeng F, Shi S. Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study. European journal of drug metabolism and pharmacokinetics. 2017 Feb;42:37-48.
2008年	Tan F, Lu L, Cai Y, Wang J, XiProteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells.pdfe Y, Wang L, Gong Y, Xu BE, Wu J, Luo Y, Qiang B, Yuan J, Sun X, Peng X. Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells. Proteomics. 8（14）:2885-96
2007年	Wang Y, Sun X, Wu J, Xu BE, Gu C, Wang H, Wang X, Tan F, Peng X, Qiang B, Yuan J, Luo Y. Casein Kinase 1alpha Interacts with RIP1 and Regulates NF-kappaB Activation. Biochemistry 47（1）:441-8.
2007年	Wang H, Wang P, Sun X, Luo Y, Wang X, Ma D, Wu J. Cloning and characterization of a novel caspase-10 isoform that activates NF-kappaB activity. Biochim Biophys Acta. 1770（11）:1528-37
2007年	Shu F, Lv S, Qin Y, Ma X, Wang X, Peng X, Luo Y, Xu BE, Sun X, Wu J. Functional characterization of human PFTK1 as a cyclin-dependent kinase. Proc Natl Acad Sci USA. 104（22）:9248-53
2007年	Xu J, Lv S, Qin Y, Shu F, Xu Y, Xu B, Sun X, Wu J. TRB3 interacts with CtIP and is overexpressed in certain cancers. Biochim Biophys Acta. 1770 （2）:273-8
2006年	Gu C, Tangye SG, Sun X, Luo Y, Lin Z, Wu J. The X-linked lymphoproliferative disease gene product SAP associates with PAK-interacting exchange factor and participates in T cell activation. Proc Natl Acad Sci USA. 103（39）:14447-52
2006年	Wang H, Sun X, Luo Y, Lin Z, Wu J. Adapter protein NRBP associates with Jab1 and negatively regulates AP-1 activity. FEBS Lett. 580（25）:6015-21
2006年	Wang J, He X, Luo Y, Yarbrough W. A novel ARF-binding protein （LZAP） alters ARF regulation of HDM2. Biochem J. 393:489-501
2003年	Wu J, Lanier L. Natural killer cells and cancer. Adv Cancer Res. 90:127-56.
2002年	Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science. 295（5558）:1291-4.